Table 1 Clinical characteristics of the primary-metastatic cohort and pathological information associated with the primary ccRCC tumor
|  | M0 at presentation (N = 57) | M1 (N = 54) | Total (N = 111) |
|---|---|---|---|
Gender | |||
 No | 15 (26.3%) | 14 (25.9%) | 29 (26.1%) |
 Yes | 42 (73.7%) | 40 (74.1%) | 82 (73.9%) |
Age at Surgery (years) | Â | ||
 Mean | 62.0 | 58.5 | 60.3 |
 Median | 63.6 | 59.1 | 61.4 |
 Range | (34.9–78.8) | (38.2–73.7) | (34.9–78.8) |
Max Tumor Size (cm) | |||
 Mean | 9.6 | 10.9 | 10.2 |
 Median | 9.0 | 10.0 | 9.5 |
 Range | (2.5–18.0) | (2.1–23.0) | (2.1–23.0) |
2010 pT | |||
 Missing | 0 | 1 | 1 |
 1A | 3 (5.3%) | 1 (1.9%) | 4 (3.6%) |
 1B | 8 (14.0%) | 8 (15.1%) | 16 (14.5%) |
 2A | 14 (24.6%) | 6 (11.3%) | 20 (18.2%) |
 2B | 4 (7.0%) | 5 (9.4%) | 9 (8.2%) |
 3A | 17 (29.8%) | 20 (37.7%) | 37 (33.6%) |
 3B | 7 (12.3%) | 4 (7.5%) | 11 (10.0%) |
 3C | 2 (3.5%) | 1 (1.9%) | 3 (2.7%) |
 4 | 2 (3.5%) | 8 (15.1%) | 10 (9.1%) |
2010 pN | |||
 0 | 18 (31.6%) | 20 (37.0%) | 38 (34.2%) |
 1 | 4 (7.0%) | 9 (16.7%) | 13 (11.7%) |
 X | 35 (61.4%) | 25 (46.3%) | 60 (54.1%) |
TNM Stage | |||
 I | 11 (19.3%) | 0 (0.0%) | 11 (9.9%) |
 II | 18 (31.6%) | 0 (0.0%) | 18 (16.2%) |
 III | 26 (45.6%) | 0 (0.0%) | 26 (23.4%) |
 IV | 2 (3.5%) | 54 (100.0%) | 56 (50.5%) |
Grade | |||
 1 | 1 (1.8%) | 1 (1.9%) | 2 (1.8%) |
 2 | 14 (24.6%) | 5 (9.3%) | 19 (17.1%) |
 3 | 32 (56.1%) | 31 (57.4%) | 63 (56.8%) |
 4 | 10 (17.5%) | 17 (31.5%) | 27 (24.3%) |
BAP1 IHC in Primary Tumor | Â | ||
 Negative | 13 (27.7%) | 6 (12.0%) | 19 (19.6%) |
 Positive | 34 (72.3%) | 44 (88.0%) | 78 (80.4%) |
 NAa |  |  | 14 |
PBRM1 IHC in Primary Tumor | |||
 Negative | 28 (60.9%) | 27 (52.9%) | 55 (56.7%) |
 Positive | 18 (39.1%) | 24 (47.1%) | 42 (43.2%) |
 NAa |  |  | 14 |
Number of Longitudinal Metastases | |||
 1 | 34 (59.6%) | 41 (75.9%) | 75 (67.6%) |
 2 | 15 (26.3%) | 12 (22.2%) | 27 (24.3%) |
 3 | 6 (10.5%) | 1 (1.9%) | 7 (6.3%) |
 4 | 2 (3.5%) | 0 (0.0%) | 2 (1.8%) |